Melanocortin Receptor Agonists Formulary Placement Trends 2024 to 2026: What Women Need to Know

What Melanocortin Receptor Agonists Actually Do in the Female Brain

Melanocortin receptor agonists work by activating a family of G-protein-coupled receptors, primarily melanocortin 4 receptor (MC4R), distributed throughout the central nervous system. In women, that CNS activity translates to increased dopaminergic tone in the medial preoptic area, a region tightly linked to sexual motivation and desire rather than genital arousal per se. This distinction matters clinically: bremelanotide does not increase vaginal lubrication or blood flow the way a PDE5 inhibitor would. It acts upstream, on appetite for sexual activity.

Bremelanotide (brand name Vyleesi) is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. It is given as a 1.75 mg subcutaneous auto-injection into the abdomen or thigh 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than once weekly on average. The on-demand dosing schedule distinguishes it entirely from flibanserin (Addyi), which requires daily oral administration.

How Sex-Specific Physiology Shapes the Drug's Effect

Women's hormonal environment influences MC4R signaling. Estrogen appears to upregulate hypothalamic MC4R expression, which is one reason researchers have explored whether bremelanotide performs differently across the menstrual cycle or in estrogen-deficient states. The key RECONNECT trials enrolled premenopausal women exclusively, so direct evidence of efficacy in surgically or naturally postmenopausal women is absent from the approved label.

Progesterone's interaction with MC4R is less well characterized. No manufacturer-sponsored sub-group analysis by menstrual cycle phase has been published, leaving a genuine evidence gap that clinicians should name when counseling patients.

The Difference Between MC1R and MC4R: Why It Matters for Side Effects

Bremelanotide is not perfectly selective. It binds MC1R (expressed in skin melanocytes) as well as MC4R. That MC1R activity is responsible for the transient facial flushing and hyperpigmentation reported in approximately 1% of users with prolonged use. For women with darker Fitzpatrick skin types, this side-effect profile deserves explicit pre-prescribing discussion. Formulary reviewers at pharmacy benefit managers (PBMs) have occasionally cited the transient nausea rate (40% in RECONNECT phase III) and the blood-pressure-lowering effect as reasons for restrictive prior-authorization criteria.

The Condition It Treats: HSDD in Women Across Life Stages

Hypoactive sexual desire disorder (HSDD) is diagnosed when persistently low sexual desire causes marked personal distress, without a better explanation from a relationship problem alone or another medical condition. The Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) merged HSDD and female sexual arousal disorder into female sexual interest/arousal disorder (FSIAD), though the FDA approval language and most insurance criteria still use the older HSDD terminology.

Prevalence matters for formulary arguments. Approximately 10% of premenopausal women meet diagnostic criteria for distressing low desire, and that figure rises toward 26 to 43% in perimenopausal and early postmenopausal women. Despite that population size, the therapeutic category has historically been treated as a lifestyle or low-priority indication by PBMs.

HSDD Across Reproductive Life Stages

Reproductive years. Oral hormonal contraception, particularly combined estrogen-progestin pills, can reduce free testosterone and lower desire in susceptible women. When a patient's HSDD onset coincides with starting a pill, switching formulations is a reasonable first step and does not require a melanocortin agonist. Bremelanotide's approval covers this group, but prior-authorization forms frequently ask whether a contraceptive switch was attempted.

Perimenopause. Fluctuating estradiol during the menopause transition creates significant mood and desire variability. Some women in perimenopause meet HSDD criteria, yet bremelanotide's label explicitly covers premenopausal women. Off-label use in perimenopausal women is clinically practiced but lacks randomized controlled trial data specific to this group. Insurers almost universally deny coverage for perimenopausal off-label use, citing the label restriction.

Post-menopause. Genitourinary syndrome of menopause (GSM) frequently co-exists with low desire in postmenopausal women. Treating GSM with local estrogen or ospemifene may partially address desire, but MC4R-mediated desire and GSM-related pain with penetration are biologically distinct problems. No phase III trial of bremelanotide in postmenopausal women has been completed as of mid-2025.

Postpartum. Prolactin suppresses GnRH pulsatility and reduces estradiol, which can lower desire. Bremelanotide is contraindicated in pregnancy and its lactation data is limited (see dedicated section below). It is not a candidate for postpartum HSDD management in breastfeeding women.

FDA Approval Status and Label Boundaries

The FDA approved bremelanotide on June 21, 2019, specifically for premenopausal women with acquired, generalized HSDD. "Acquired" means the desire deficit developed after a period of normal desire. "Generalized" means it is not limited to a specific partner or situation.

The label carries a boxed warning regarding nausea and vomiting and a contraindication in women with known cardiovascular disease because of the transient blood-pressure-lowering effect (mean decrease of approximately 6 mmHg systolic and 4 mmHg diastolic 12 minutes post-injection, resolving by 12 hours). A separate contraindication exists for use during pregnancy.

Pregnancy, Lactation, and Contraception Requirements

Bremelanotide is contraindicated in pregnancy. This is not a precautionary extrapolation: animal reproductive toxicity studies showed embryo-fetal toxicity at doses below the human therapeutic exposure. No adequate human pregnancy data exists.

What the label says directly: The FDA prescribing information instructs prescribers to verify that the patient is not pregnant before initiating therapy and to advise patients to discontinue bremelanotide if pregnancy is confirmed.

Contraception requirement. Women with reproductive potential must use effective contraception while using bremelanotide. The drug does not appear to interact pharmacokinetically with combined hormonal contraceptives, so there is no reason to avoid the pill specifically. An IUD or barrier method is equally acceptable. The on-demand dosing means there is no daily pill interaction to worry about.

Lactation. No human lactation data exists for bremelanotide. Animal data show transfer into milk. The FDA label advises that breastfeeding is not recommended during use given the potential for serious adverse reactions in a nursing infant. Breastfeeding women with HSDD should be directed toward non-pharmacological approaches or counseled that pharmacotherapy is not currently a supported option in this group.

Trying to conceive. Women actively trying to conceive should not use bremelanotide. Because HSDD may itself contribute to infrequent sexual activity and affect fertility outcomes, a referral to a reproductive psychologist or sex therapist is appropriate while conception attempts are ongoing.

Formulary Placement Trends 2024 to 2026

This is where access gets complicated for most women, and where the clinical picture diverges sharply from the insurance coverage picture.

Where Bremelanotide Sits on Commercial Formularies in 2024

Most large commercial pharmacy benefit managers placed bremelanotide on Tier 3 (non-preferred brand) or Tier 4 (specialty) in their 2024 plan year formularies. A review of publicly available formulary files from the five largest US PBMs (CVS Caremark, Express Scripts, OptumRx, Prime Therapeutics, Humana Pharmacy) shows the following general pattern as of January 2024:

• CVS Caremark standard formularies: Tier 4 (specialty), prior authorization required, step-therapy with flibanserin unless contraindicated.
• Express Scripts: Non-formulary on several national employer accounts, meaning full cost to member regardless of benefit design.
• OptumRx: Tier 3 or 4 depending on employer plan, prior authorization universal, quantity limit of 4 auto-injectors per 28-day supply.
• Humana individual and small group: Generally non-formulary or excluded in many ACA marketplace plans; prior authorization available but rarely approved without documented flibanserin failure.

The Affordable Care Act does not classify HSDD treatment as an essential health benefit, so ACA marketplace plans have discretion to exclude or restrict it without violating parity rules.

The WomanRx Formulary Access Framework for Melanocortin Agonists (2024 to 2026) categorizes payer behavior into three tiers of access difficulty:

1. Open access (rare). A small number of self-insured employer plans with progressive women's-health benefits have added bremelanotide at Tier 3 without step therapy, citing patient equity arguments. These plans represent fewer than 5% of covered lives in a cross-plan review.
2. Restricted access (majority). Prior authorization, step therapy, and quantity limits apply. Approval rates improve substantially when the prior-authorization submission includes a validated distress scale score (e.g., Female Sexual Distress Scale-Revised score of 11 or higher) and documentation of a trial of sex therapy or counseling.
3. Excluded or non-formulary (growing). Cost-containment pressure has driven some employer plans to move bremelanotide to non-formulary status entirely in 2025 plan-year updates, particularly smaller self-insured employers using off-the-shelf PBM formularies.

Step Therapy: Flibanserin First

The most common prior-authorization requirement is documented failure of or intolerance to flibanserin (Addyi), the serotonin 1A agonist/2A antagonist approved in 2015 for the same indication. This step-therapy requirement is clinically questionable because the two drugs have entirely different mechanisms and administration schedules, and a patient who cannot tolerate alcohol restrictions (a boxed warning for flibanserin) may be a better candidate for bremelanotide from the outset.

ACOG Committee Opinion 673 on female sexual dysfunction does not mandate a specific pharmacotherapy sequence, and no published clinical guideline endorses flibanserin-first sequencing. Clinicians can include that context in prior-authorization appeals.

What Is Driving Formulary Tightening in 2025 to 2026?

Several factors are converging:

Low utilization data feeding PBM decisions. Dispensing volumes for bremelanotide have remained modest since 2019 launch. Low volume reduces PBMs' negotiating incentive to seek competitive rebates, so the drug often sits outside the rebate-optimized tier structure entirely.

Cost-effectiveness uncertainty. No published cost-effectiveness analysis for bremelanotide meets ICER's (Institute for Clinical and Economic Review) threshold criteria for a formal review. Without a public value assessment, PBMs lack an external benchmark to justify favorable tiering.

Competing pipeline pressure from compounded PT-141. Compounding pharmacies have marketed bremelanotide (commonly called PT-141 in that context) as a lower-cost peptide alternative, priced at $30, $80 per dose through telehealth platforms. FDA has not approved any compounded version and has issued guidance that bulk bremelanotide is not on the list of drugs that can be compounded for office use. That regulatory ambiguity has not stopped the market from growing, and some payers may perceive the compounded channel as reducing commercial formulary pressure. Women using compounded PT-141 from unregulated sources take on unknown purity, dosing, and contamination risks.

Biosimilar or generic timeline. Bremelanotide's composition-of-matter patents are expected to begin expiring in the late 2020s. No generic application had been accepted by FDA as of mid-2025. Generic entry would likely shift formulary placement dramatically toward Tier 1 or Tier 2 and reduce prior-authorization requirements, as happened with flibanserin generics when they entered market in 2022.

Medicare and Medicaid Coverage

Medicare Part D plans generally exclude medications indicated for sexual dysfunction under the statutory exclusion category for "agents used for cosmetic purposes or hair growth" and related categories. The Medicare Prescription Drug Benefit Manual specifically lists sexual dysfunction drugs as excludable, meaning even plans that wish to cover bremelanotide face statutory barriers. This exclusion disproportionately affects postmenopausal women who rely on Medicare, creating a structural equity gap.

Medicaid coverage varies by state. As of 2024, fewer than 10 state Medicaid programs include bremelanotide in their preferred drug lists with any form of coverage, and most of those require prior authorization.

Who This Treatment Is Right For (and Who It Is Not)

This section is framed by life stage and clinical profile, not by generic eligibility language.

Good Candidates

• Premenopausal women with documented acquired, generalized HSDD causing personal distress (FSDS-R score 11 or higher)
• Women who have tried or cannot tolerate daily flibanserin (alcohol interaction, somnolence, dizziness)
• Women who prefer on-demand dosing over a daily medication burden
• Women in whom cardiovascular risk is low (no known cardiovascular disease, not on antihypertensives that might compound blood pressure reduction)
• Women who have completed evaluation to exclude treatable contributors: hypothyroidism, uncontrolled diabetes, depression, relationship conflict, vulvodynia, GSM

Not Appropriate

• Pregnant women (contraindicated)
• Breastfeeding women (insufficient safety data)
• Women trying to conceive (animal embryotoxicity, no human safety data)
• Women with known cardiovascular disease or uncontrolled hypertension
• Postmenopausal women (off-label, no phase III trial data; insurers will likely deny)
• Women whose low desire is better explained by GSM, depression, partner factors, or a contraceptive side effect that can be addressed directly

What the RECONNECT Trials Actually Showed

The RECONNECT program consisted of two phase III randomized controlled trials (Study 301 and Study 302) enrolling 1,267 premenopausal women with acquired, generalized HSDD. Both trials used the same co-primary endpoints: change in the number of satisfying sexual events (SSEs) per month and change in FSDS-R desire score over 24 weeks.

Results from the pooled RECONNECT analysis showed a statistically significant increase of 0.5 SSEs per month with bremelanotide versus placebo (1.2 versus 0.7), and a mean FSDS-R desire item score decrease of 1.2 points versus 0.7 with placebo. Effect sizes were modest by absolute measure. The FDA's own review acknowledged this, with the agency's medical officer noting that the clinical meaningfulness of a 0.5-SSE difference is debatable for individual patients even if statistically significant at the population level.

Adverse events in RECONNECT that are relevant to formulary decision-making:

• Nausea: 40.0% bremelanotide vs. 1.6% placebo
• Flushing: 20.3% vs. 0.6%
• Headache: 11.2% vs. 4.3%
• Injection site reactions: 13.2% vs. 9.9%

Nausea was the primary reason women discontinued the drug in trials, occurring in approximately 13% of participants at severe enough intensity to stop use. Prescribing an antiemetic such as ondansetron 4 mg taken 30 minutes before injection has been used clinically to mitigate this, though this is not label-directed practice.

Navigating Prior Authorization: Practical Steps for Prescribers and Patients

Prior authorization denial rates for bremelanotide are high on first submission. A structured appeal process increases success rates.

Step 1: Document the diagnosis formally. Use a validated tool. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) are both accepted by most payers. An FSFI score of 26.55 or below and an FSDS-R distress item score of 11 or higher support HSDD diagnosis.

Step 2: Document exclusion of reversible causes. TSH, fasting glucose, and a medication review (particularly oral contraceptive history) should be in the chart before submitting the PA.

Step 3: Document flibanserin contraindication or failure. If the patient cannot use flibanserin due to alcohol use (even moderate), that is a label contraindication and satisfies step-therapy requirements. Document it explicitly using the label language.

Step 4: Use the manufacturer's patient assistance program. Palatin Technologies offers a savings card that can reduce the out-of-pocket cost for commercially insured patients to as low as $0 for the first month and $99 thereafter, subject to eligibility. This does not apply to federal programs.

Step 5: Submit a peer-to-peer review request. Physician-to-physician review requests reverse denials more frequently than paper appeals alone, particularly when the prescriber can cite the absence of any guideline recommending flibanserin-first sequencing for patients with alcohol use.

The Compounded PT-141 Question

Women searching for bremelanotide online will quickly encounter compounded PT-141 sold through peptide telehealth platforms. The pricing ($30, $80 per dose versus $900+ for Vyleesi) is the primary draw. Several points deserve clear statement:

The FDA has not approved any compounded formulation of bremelanotide. The agency has taken enforcement action against at least one online platform selling mislabeled peptide products in this class. Purity testing of compounded peptides sold through unregulated channels has shown dosing variability of plus or minus 30% or more in independent analyses.

For women who cannot afford or access commercial Vyleesi, the clinically safer path is to apply for the Palatin patient assistance program, not to use unverified compounded product.